Table 1. Sex and Age-Matched Nested Case-Control Study of Thyroid Dysfunction in Chronic Hepatitis C Patients Received IFN-α-Based Therapy.
| Patients With TD (n = 68) | Nested Control Group (n = 68) | P value | |
|---|---|---|---|
| ALT level , IU / L, median (range) | 152 (69-267) | 171 (56-301) | 0.238 a |
| HCV RNA , IU/mL ×103, median (range) | 625 (0.20-14200) | 607 (0.30-1250) | 0.553 a |
| Diagnosis, No. (%) | 0.598 b | ||
| CHC without cirrhosis | 43 (63.2) | 40 (58.8) | |
| LC | 25 (36.8) | 28 (41.2) | |
| HCV genotype, No. (%) | 0.605 b | ||
| Type 1b | 36 (52.9) | 39 (57.4) | |
| Non-type 1 (Type 2/3/6) | 32 (47.1) | 29 (42.6) | |
| IFN-α- based therapy type, No. (%) | 0.463 b | ||
| Regular IFN-α monotherapy | 7 (10.3) | 5 (7.4) | |
| Regular IFN-α + ribavirin | 14 (20.5) | 13 (19.1) | |
| Peg-IFN-α + ribavirin | 47 (69.1) | 50 (73.5) | |
| Pretreatment TPOAb, No. (%) | 0.007 b | ||
| Positive | 15 (22.1) | 4 (5.9) | |
| Negative | 53 (77.9) | 64 (94.1) |
Abbreviations: ALT, alanine aminotransferase; CHC, chronic hepatitis C;HCV, hepatitis C virus; IFN-α, interferonalpha; LC, liver cirrhosis;Peg-IFN-α, pegylated interferonalpha;TD, thyroid dysfunction;TPOAb, thyroid peroxidase antibody.
aP value was given for the comparison between patients without TD and patients with TD by a Student’s t-test.
bP value was given for the comparison between patients without TD and patients with TD by a χ2 test.